Amgen Inc. (NASDAQ:AMGN) Shares Acquired by Personal CFO Solutions LLC

Personal CFO Solutions LLC boosted its holdings in Amgen Inc. (NASDAQ:AMGN) by 4.1% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,787 shares of the medical research company’s stock after purchasing an additional 110 shares during the quarter. Personal CFO Solutions LLC’s holdings in Amgen were worth $619,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Strategic Investment Solutions Inc. IL purchased a new stake in shares of Amgen in the first quarter valued at about $28,000. PrairieView Partners LLC raised its stake in Amgen by 250.0% during the 2nd quarter. PrairieView Partners LLC now owns 140 shares of the medical research company’s stock valued at $31,000 after acquiring an additional 100 shares during the last quarter. Lumature Wealth Partners LLC lifted its position in Amgen by 51.1% during the 1st quarter. Lumature Wealth Partners LLC now owns 142 shares of the medical research company’s stock worth $34,000 after acquiring an additional 48 shares during the period. Guardian Wealth Advisors LLC acquired a new stake in Amgen during the 1st quarter worth approximately $37,000. Finally, Impact Partnership Wealth LLC purchased a new position in shares of Amgen in the 2nd quarter valued at approximately $37,000. Institutional investors and hedge funds own 74.44% of the company’s stock.

Insider Transactions at Amgen

In other news, major shareholder Amgen Inc acquired 1,764,705 shares of Amgen stock in a transaction that occurred on Tuesday, September 19th. The shares were acquired at an average price of $17.00 per share, with a total value of $29,999,985.00. Following the completion of the purchase, the insider now owns 35,368,653 shares of the company’s stock, valued at approximately $601,267,101. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other Amgen news, EVP Jonathan P. Graham sold 10,000 shares of Amgen stock in a transaction dated Wednesday, November 8th. The stock was sold at an average price of $272.81, for a total value of $2,728,100.00. Following the completion of the sale, the executive vice president now owns 28,078 shares in the company, valued at approximately $7,659,959.18. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Amgen Inc acquired 1,764,705 shares of the business’s stock in a transaction dated Tuesday, September 19th. The shares were bought at an average price of $17.00 per share, for a total transaction of $29,999,985.00. Following the completion of the acquisition, the insider now owns 35,368,653 shares in the company, valued at $601,267,101. The disclosure for this purchase can be found here. Insiders own 0.46% of the company’s stock.

Amgen Trading Down 1.3 %

Shares of Amgen stock opened at $265.39 on Friday. Amgen Inc. has a 1 year low of $211.71 and a 1 year high of $291.60. The company has a debt-to-equity ratio of 7.71, a current ratio of 2.86 and a quick ratio of 2.56. The business has a 50 day moving average price of $269.59 and a 200 day moving average price of $247.35. The company has a market capitalization of $142.03 billion, a P/E ratio of 18.86, a P/E/G ratio of 2.61 and a beta of 0.58.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, October 31st. The medical research company reported $4.96 earnings per share for the quarter, topping analysts’ consensus estimates of $4.65 by $0.31. Amgen had a return on equity of 165.37% and a net margin of 28.20%. The company had revenue of $6.90 billion during the quarter, compared to analysts’ expectations of $6.92 billion. During the same period in the previous year, the firm posted $4.70 earnings per share. The business’s revenue for the quarter was up 3.7% compared to the same quarter last year. Sell-side analysts anticipate that Amgen Inc. will post 18.65 EPS for the current fiscal year.

Amgen Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, December 8th. Shareholders of record on Friday, November 17th will be paid a dividend of $2.13 per share. The ex-dividend date is Thursday, November 16th. This represents a $8.52 annualized dividend and a dividend yield of 3.21%. Amgen’s dividend payout ratio is currently 60.55%.

Wall Street Analysts Forecast Growth

AMGN has been the subject of several recent research reports. JPMorgan Chase & Co. reaffirmed a “neutral” rating and set a $270.00 price target on shares of Amgen in a report on Friday, October 20th. Wells Fargo & Company lifted their target price on shares of Amgen from $265.00 to $320.00 in a report on Thursday, October 12th. Royal Bank of Canada increased their price target on shares of Amgen from $253.00 to $256.00 and gave the stock a “sector perform” rating in a report on Wednesday, November 1st. Morgan Stanley lowered their price objective on Amgen from $300.00 to $291.00 and set an “equal weight” rating on the stock in a report on Wednesday, November 1st. Finally, StockNews.com assumed coverage on Amgen in a research note on Thursday, October 5th. They set a “strong-buy” rating for the company. Two analysts have rated the stock with a sell rating, eight have issued a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $278.15.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.